Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study - Wikidata - wikimedia - TriplyDB

Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study

Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study

http://www.wikidata.org/entity/Q35800437

about

Clinical and experimental applications of sodium phenylbutyrate Sodium phenylbutyrate controls neuroinflammatory and antioxidant activities and protects dopaminergic neurons in mouse models of Parkinson's disease Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors The clinical development of histone deacetylase inhibitors as targeted anticancer drugs.Glutamine targeting inhibits systemic metastasis in the VM-M3 murine tumor model.Interpreting clinical assays for histone deacetylase inhibitors.Sequential treatment with 5-aza-2'-deoxycytidine and deacetylase inhibitors reactivates HIV-1.Potential for therapeutic manipulation of the UPR in disease.Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma.Histone deacetylase inhibitors in lymphoma and solid malignancies.Ciprofloxacin is an inhibitor of the Mcm2-7 replicative helicase.A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gliomas.Targeting histone deacetylases for the treatment of disease The chemical chaperone 4-phenylbutyrate inhibits adipogenesis by modulating the unfolded protein response.Phase II clinical and pharmacologic study of radiation therapy and carboxyamido-triazole (CAI) in adults with newly diagnosed glioblastoma multiforme The role of targeted therapies in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.Impact of Histone Deacetylase Inhibitors on microRNA Expression and Cancer Therapy: A Review.An update on the use of benzoate, phenylacetate and phenylbutyrate ammonia scavengers for interrogating and modifying liver nitrogen metabolism and its implications in urea cycle disorders and liver disease.4-Phenylbutyrate inhibits tunicamycin-induced acute kidney injury via CHOP/GADD153 repression Growth inhibitory effect of 4-phenyl butyric acid on human gastric cancer cells is associated with cell cycle arrest.Complementary effects of HDAC inhibitor 4-PB on gap junction communication and cellular export mechanisms support restoration of chemosensitivity of PDAC cells.Study of Antitumor Activity of Sodium Phenylbutyrate, Histon Deacetylase Inhibitor, on Ehrlich Carcinoma Model.Phenotype-genotype correlations in patients with Marinesco-Sjögren syndrome.Radiation protection and mitigation potential of phenylbutyrate: delivered via oral administration.Phase 2 study of sodium phenylbutyrate in ALS.Histone deacetylase inhibitors in cancer therapy

P2860

Q24613511-EC0DABD4-A6CF-4D62-AF99-2A6DDAC61228 Q27301885-10F7D94F-60D3-47D0-8854-77989CA44DCB Q33288097-B8E38D9F-9D0A-4554-BBA2-F586CFD79793 Q33752772-C43C5DBB-C7AB-4347-9D6A-7F651B643190 Q33829390-7295F79D-554B-488F-BFF9-508AEFF3CB81 Q34158731-06053308-43A0-422B-90F0-E2D8869DD174 Q35003657-799648B5-11A7-4233-8189-2A384445A042 Q36525896-C28DA44A-24F8-4D2E-BF5C-B33D990D1676 Q36809416-52F2F1AD-8BFF-48D7-8155-F37C17957399 Q37036925-759B9F2D-886D-4AFB-A260-2833BA37C6D2 Q37118947-BD2D6C31-34D8-4E93-BA48-B4FF11DF84C5 Q37218789-B58DC79B-EA0A-424A-B6D2-C226B2F5E410 Q37262792-9F076057-FE59-4306-A9D6-0C7733A400B4 Q37296159-E1FC8EB2-ECDE-4C50-A28B-DA6CE4E0D5F7 Q37430626-686C9868-C455-4C32-979C-BE0D7844DE60 Q37659384-9F832CBA-9494-43D1-BE14-041115F4359D Q38205134-82754BC4-CD36-4504-BC4E-3230C64EE445 Q38572855-5C83FEB3-2909-462E-B0EC-2310A37A72E0 Q39012545-F76BF6CB-7590-4573-984C-53802EEB2B22 Q39035105-1607CE39-185C-44B7-AABC-691E08A035AB Q39415285-EB3713B2-CDA0-4E16-B1C7-AFB79303EE0D Q40197237-160C84AC-B712-4A26-92F2-546E9F93CB8B Q41220433-4BDCE9F1-8392-4D1E-A636-3D99844E4731 Q44533587-53A6CE86-87E3-4E1F-ABA6-97562264E536 Q46330013-004B199E-B5F1-439A-826D-C639E0837AE1 Q46439340-1BD21AE9-AC28-4454-A1E5-EA16D2DB1B8A Q57272462-67AE0502-DCD9-4AFC-AF5A-300E6ABB925C

P2860

Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study

http://www.wikidata.org/entity/Q35800437

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Oral sodium phenylbutyrate in ...... lation and pharmacologic study

@ast

Oral sodium phenylbutyrate in ...... lation and pharmacologic study

@en

type

label

Oral sodium phenylbutyrate in ...... lation and pharmacologic study

@ast

Oral sodium phenylbutyrate in ...... lation and pharmacologic study

@en

prefLabel

Oral sodium phenylbutyrate in ...... lation and pharmacologic study

@ast

Oral sodium phenylbutyrate in ...... lation and pharmacologic study

@en

P1433

Q35800437-9217CE27-8839-4FD5-B8C6-6D128EB8C2A9

P1476

Q35800437-FF03FC99-0FBE-4304-A36A-EBE6885A82DF

P2093

Q35800437-22566D36-9E6D-4E2E-BD44-3B7D81280901

Q35800437-34ABE18C-922B-4D5E-9068-1E7CAD220F73

Q35800437-5ABF6060-DB1D-4E8D-9AA3-8BC520E2B722

Q35800437-AD220DD0-85FD-4849-9F48-96D3BF09FA58

Q35800437-B668AD70-8264-477B-8E4E-489C207A807F

Q35800437-F15580B3-C815-4354-8C97-A5C9EEDE2978

P2860

Q35800437-0C739E97-C879-499E-B146-527A3D874664

Q35800437-2AA2E274-2AAB-4686-926A-151A089A6C45

Q35800437-2AE41F3C-3BAD-4ED7-86F4-5BC57D233D01

Q35800437-49559113-0362-4808-88F6-C02B9FF78EA3

Q35800437-5A52CA82-EF3C-44AD-B9FE-F85EFA6E944D

Q35800437-6091F6F0-7240-4EE8-A6AB-D7B17D977C11

Q35800437-6B6A7DDB-0129-4FF0-8606-6BD0F95CEE21

Q35800437-A8CB9D3F-383F-454F-B0AF-1CDA9A77F2BC

Q35800437-AD81C55C-24BE-40B9-B063-34F8C39E29C4

Q35800437-B26933FA-FE20-42C5-B6DC-6E2D743AD334

P304

Q35800437-4648F51B-1085-4C06-9EB5-5F9CD4AE7090

P31

Q35800437-F9F0C474-45A2-4CAD-A9B2-F7A9D9219566

P356

Q35800437-E961EDFD-560B-41E1-97F6-77A0489AD31E

P433

Q35800437-603E6602-8570-4623-B1DD-62B0C769DB99

P478

Q35800437-8CD2AE80-DFD3-4F8F-A512-4518CD23C187

P50

Q35800437-44CF9D75-63E3-4390-B5E5-6AEB243B24E8

P577

Q35800437-6E20A564-23E1-4EE6-B571-038BC13C7661

P698

Q35800437-AA776786-B251-497D-ABB2-19ED8B00D2C4

P932

Q35800437-49917200-CC3F-472C-842C-36ED524F17B1

P356

S1152851704000183

P1433

P1476

Oral sodium phenylbutyrate in ...... lation and pharmacologic study

@en

P2093

Joy D Fisher

http://www.w3.org/2001/XMLSchema#string

Kathryn A Carson

http://www.w3.org/2001/XMLSchema#string

Mark R Gilbert

http://www.w3.org/2001/XMLSchema#string

Michael A Carducci

http://www.w3.org/2001/XMLSchema#string

Stuart A Grossman

http://www.w3.org/2001/XMLSchema#string

Surasak Phuphanich

http://www.w3.org/2001/XMLSchema#string

P2860

Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma

Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate.

Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11.

Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. New Approaches to Brain Tumor Therapy Central Nervous System Consortium.

Clinical use of differentiating agents in cancer therapy.

Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia.

Phenylacetate synergizes with retinoic acid in inducing the differentiation of human neuroblastoma cells.

Phase II study of phenylacetate in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report.

A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies.

A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule.

P304

177-182

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1215/S1152851704000183

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Sharyn D. Baker

P577

2005-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15831235

http://www.w3.org/2001/XMLSchema#string

P932

1871887

http://www.w3.org/2001/XMLSchema#string